The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: a retrospective study.

Background: Recently several alternative forms of the original clopidogrel hydrogensulfate (CHS) were spread worldwide. A large amount of such drugs turned out to be clopidogrel besylate (CB). Only three studies, involving healthy volunteers, investigated the antiplatelet effect of CB, whereas its attribute remained unexplored in the case of patients with cardiovascular diseases. This retrospective study aimed to evaluate the difference between the antiplatelet effects of two clopidogrel formulas, CHS and CB, on patients with coronary artery diseases. Methods: Data of 150 patients with previous CHS treatment were investigated. According to the documentations, the CHS therapy was shifted to CB. 94 patients of the selected population received dual antiplatelet therapy, clopidogrel and aspirin. The antiplatelet effects of CHS and CB were compared by ADP induced platelet aggregation measurements using light transmission aggregometry. Results: Irrespective of the therapeutic combinations the performed statistical investigations failed to show significant difference (p=0.30) between the effect of CB (AGGmax(CB): 27.6 +/- 13.7%) or CHS (AGGmax(CHS): 29.0 +/- 15.3%) on the ADP induced platelet aggregation. Insignificant deviations were found in both forms of clopidogrel salts, either in the lack (AGGmax(CB) : 32.5 +/- 14,2%; AGGmaxCHS: 34,0 +/- 16,1%; p=0,29) or in the presence of aspirin (AGGmax(CB): 24.7 +/- 12,5%; AGGmax(CHS): 26,0 +/- 14,1%; p=0,31). Conclusion: Our results indicated that both CB and CHS had an identical inhibitory effect on ADP induced platelet aggregation in patients with cardiovascular diseases. Moreover their efficiency showed no overall significant difference in the case of dual antiplatelet therapy with aspirin as well. However there might be an inter-and intraindividual variability between the two clopidogrel formulas. (C) 2011 Elsevier Ltd. All rights reserved.